Oct 18 (Reuters) - The federal trial judge overseeing a four-year-old multidistrict litigation over Merck’s Zostavax shingles vaccine decided in March 2022 that it was time for plaintiffs to put up or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback